Clinical Trials · NCT04356430
Neoadjuvant Therapy of Abiraterone Plus ADT for High Risk Prostate Cancer
- Phase
- Phase 2
- Recruitment status
- Unknown
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- Enrollment
- 75
- Start date
- Apr 2019
- Locations
- 1 site, China
- Primary endpoint
- Pathologic Complete Response Rate